Results 91 to 100 of about 216,694 (240)

Immune Complexes Shape the Pathogenicity of Autoantibodies in Systemic Autoimmune Diseases: Insights From an FcγRIIIA‐Reporter Assay

Arthritis &Rheumatology, EarlyView.
Objective Immune complexes (ICs), formed by autoantigen and autoantibody, play a pathogenic role in systemic autoimmune diseases through stimulation of Fcγ receptors (FcγR). However, studies investigating bioactivity of circulating ICs across various diseases remain limited.
Koji Suzuki, Masaru Takeshita, Yuki Imai, Hiroyuki Fukui, Kazunori Furuhashi, Kotaro Matsumoto, Jun Kikuchi, Keiko Yoshimoto, Yuko Kaneko   +8 more
wiley   +1 more source

Epidemiology of Multiple Sclerosis in Fars Province

مجله اپیدمیولوژی ایران, 2014
Background & Objectives : Multiple Sclerosis is a chronic progressive disease with several disabilities for patients. Its distribution in the world can be an important clue to study racial, genetic, and environmental factors; thus, epidemiologic studies ...
S Izadi, AR Nikseresht, M Poursadeghfard
doaj  

Safety and Efficacy of Fingolimod in Treatment-Naïve Multiple Sclerosis Patients

Journal of Central Nervous System Disease, 2011
Fingolimod was recently approved for use in the United States after two phase III trials confirmed its effectiveness in reducing disease activity in relapsing-remitting multiple sclerosis. These positive results, coupled with the important fact that this
James J. Marriott
doaj   +1 more source

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source

Fingolimod in the treatment of relapsing–remitting multiple sclerosis: long-term experience and an update on the clinical evidence

Therapeutic Advances in Neurological Disorders, 2016
Since the approval in 2010 of fingolimod 0.5 mg (Gilenya; Novartis Pharma AG, Basel, Switzerland) in the USA as an oral therapy for relapsing forms of multiple sclerosis, long-term clinical experience with this therapy has been increasing.
Bhupendra O. Khatri
doaj   +1 more source

Improved cognitive outcomes in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study

Multiple Sclerosis, 2017
Background: Cognitive impairment is common in multiple sclerosis (MS), with cognitive processing speed being the most frequently affected domain. Objective: Examine the effects of daclizumab beta versus intramuscular (IM) interferon (IFN) beta-1a on ...
R. Benedict, S. Cohan, S. Lynch, K. Riester, Ping Wang, Wanda Castro-Borrero, J. Elkins, G. Sabatella   +7 more
semanticscholar   +1 more source

Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis

British Journal of Clinical Pharmacology, EarlyView.
Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley   +1 more source

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

Multiple Sclerosis, 2015
Background: ‘No evidence of disease activity’ (NEDA), defined as absence of magnetic resonance imaging activity (T2 and/or gadolinium-enhanced T1 lesions), relapses and disability progression (‘NEDA-3’), is used as a comprehensive measure of treatment ...
L. Kappos, N. de Stefano, M. Freedman, B. Cree, E. Radue, T. Sprenger, M. Sormani, Terence Smith, D. Häring, Daniela Piani Meier, Davorka Tomic   +10 more
semanticscholar   +1 more source

Long‐term prognosis of pharmacotherapy in newly diagnosed focal epilepsy patients and the predictive value of baseline seizure timing: A prospective cohort study

Epilepsia, EarlyView.
Abstract Objective Epilepsy is a highly heterogeneous neurological disorder with significant prognostic variability. Accurate long‐term outcome prediction remains a clinical challenge. We investigated pharmacotherapeutic prognosis and key predictors, particularly baseline seizure timing, to guide individualized treatment.
Lei Sun, Shouye Sun, Xinyue Zhang, Weihong Lin   +3 more
wiley   +1 more source

Non-traumatic Acute Epidural Hematoma in Multiple Sclerosis Treated With Fingolimod

Frontiers in Neurology, 2019
Fingolimod acts as a functional antagonist of the sphingosine-1-phosphate receptor and is widely used for relapsing-remitting multiple sclerosis (MS).
Ryoko Fukai, Keita Takahashi, Hiroyuki Abe, Yuichi Higashiyama, Hiroshi Doi, Hideyuki Takeuchi, Fumiaki Tanaka   +6 more
doaj   +1 more source